PTC THERAPEUTICS, INC. (PTCT) research
PTC THERAPEUTICS, INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $63.46
- As of
PTC THERAPEUTICS, INC. (PTCT): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-21.
As of . Source: SEC EDGAR filings for PTCT. Method and limitations.
Share the PTCT intelligence card
See the full PTCT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PTCT on one page. Preview it with sample data, then open it live with a free account.
Preview the PTCT dossierActive signals for PTCT
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +107% to PTCT (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +64% to PTCT (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +9740% to PTCT (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 61% of PTCT (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 116.4%, EPS $0.92 vs $0.4252 estimate
FREE, NO ACCOUNT
Every signal on PTCT, as it fires
You are seeing 5 of 10 signals recorded on PTCT since 2026-05-16.
The five above landed across 2 days. The other 5 were recorded on 2 other days. 5 of the 10 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PTCT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 69366J200 · 2026Q2 | $126.3M | 0.06% | , |
| CITADEL ADVISORS LLCCUSIP 69366J200 · 2026Q2 | $61M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 69366J200 · 2026Q2 | $59M | 0.08% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 69366J200 · 2026Q2 | $3.8M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 69366J200 · 2026Q2 | $869K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PTCT
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
PTCT against its peers
PTCT's operating margin of 50.1% ranks in the 96th percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | PTCT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.7B USD | 147M USD | 97 | 15 |
| Operating margin | 50.1% | -153.1% | 96 | 13 |
| Net margin | 39.4% | -148.4% | 89 | 13 |
| Return on equity | n/a | -32.1% | n/a | 23 |
| P / E | 8.2x | n/a | n/a | 2 |
Peers (24): COGT, CRSP, TVTX, ORKA, MIRM, APLS, DFTX, ERAS, MANE, KOD, SRRK, IOVA, CGON, DNTH, GRAL, CNTA, LGND, BLTE, ALKS, RYTM, IMVT, EWTX, VKTX, TNGX. Left out: BCHMY (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (PTCT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow PTCT on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to PTCT for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.